Acute Antibody-mediated Rejection 1 Week After Lung Transplantation Successfully Treated With Eculizumab, Intravenous Immunoglobulins, and Rituximab
- 1 June 2018
- journal article
- letter
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (6) , e301-e303
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart RejectionCirculation, 2017
- Lung intragraft donor-specific antibodies as a risk factor for graft lossThe Journal of Heart and Lung Transplantation, 2016
- De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcomeThe Journal of Heart and Lung Transplantation, 2016
- Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2016
- Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibody CharacteristicsAmerican Journal of Transplantation, 2016
- The Challenge of Acute Antibody-Mediated Rejection in Kidney TransplantationTransplantation, 2016
- Eculizumab to Treat Antibody-Mediated Rejection in a 7-Year-Old Kidney Transplant RecipientPediatrics, 2015
- Implications for Human Leukocyte Antigen Antibodies After Lung TransplantationChest, 2013
- Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumabThe Journal of Heart and Lung Transplantation, 2012
- Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant RecipientsAmerican Journal of Transplantation, 2011